- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05239143
P-MUC1C-ALLO1 Allogene CAR-T-celler i behandling af forsøgspersoner med avancerede eller metastatiske faste tumorer
En fase 1-dosiseskalering og udvidet kohorteundersøgelse af P-MUC1C-ALLO1 i voksne forsøgspersoner med avancerede eller metastatiske solide tumorer
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is an open label, multi-center Phase 1 study that will follow a 3 + 3 design of dose-escalating cohorts of single and multiple doses of P-MUC1C-ALLO1 to determine a Recommended Phase 2 Dose (RP2D). P-MUC1C-ALLO1 is an allogeneic chimeric antigen receptor (CAR) T cell therapy designed to target cancer cells expressing Mucin1 cell surface associated C-Terminal (MUC1-C) antigen. Additional participants will be treated with P-MUC1C-ALLO1 at the determined RP2D.
Following enrollment, subjects will be treated with P-MUC1C-ALLO1 and will undergo serial measurements of safety, tolerability and response. Rimiducid may be administered as indicated.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Irvine, California, Forenede Stater, 92868
- University of California, Irvine Medical Center
-
Los Angeles, California, Forenede Stater, 90048
- Cedars Sinai Medical Center
-
San Diego, California, Forenede Stater, 92037
- University of California, San Diego
-
San Francisco, California, Forenede Stater, 94143
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80218
- Sarah Cannon Research Institute at HealthONE
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Westwood, Kansas, Forenede Stater, 66205
- University of Kansas Cancer Center
-
Wichita, Kansas, Forenede Stater, 67214
- Cancer Center of Kansas
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21201
- University of Maryland Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Dana Farber Cancer Institute
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- University of Nebraska Medical Center
-
-
New York
-
The Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, Forenede Stater, 78229
- NEXT Oncology
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Males or females, Subjects ≥18 years with life expectancy >3 months
- Must have a confirmed diagnosis of unresectable, locally advanced or metastatic epithelial-derived cancer
- Must have progressed during or after last therapy, developed intolerance/toxicity to current treatment, or ineligible or refused other existing treatment options, and have measurable disease
- Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 or Karnofsky performance status ≥70%
- Must have adequate vital organ function within pre-determined parameters
- Must have archived tumor tissue available or consent to a biopsy collection
- Must be willing to practice birth control
- Must have a negative pregnancy test at screening and prior to initiating lymphodepletion chemotherapy or study drug administration
- Must have recovered from toxicities due to prior therapies
Exclusion Criteria:
- Has inadequate venous access
- Has an active second malignancy (not disease free for at least 5 years) in addition to the studied malignancy, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell skin carcinoma
- Is pregnant or lactating
- Has a history of or active autoimmune disease
- Has a history of significant central nervous system (CNS) disease, such as stroke, epilepsy
- Has an active systemic (viral, bacterial, or fungal) infection
- Has New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of myocardial infarction or significant arrhythmia
- Has any psychiatric or medical disorder that would preclude safe participation in and/or adherence to the protocol
- Has received anticancer medications within 2 weeks of the time of initiating lymphodepletion
- Has received immunosuppressive medications within 2 weeks of administration of P-MUC1C-ALLO1, and/or expected to require them while enrolled in the study
- Has received systemic corticosteroid therapy within 1 week of the administration of P-MUC1C-ALLO1 or is expected to require it during the course of the study
- Has known CNS metastases or symptomatic CNS involvement
- Has a history of significant liver disease or active liver disease
- Has a history of known genetic predisposition to HLH/MAS
- Has received anti-cancer monoclonal antibody therapy within 4 weeks of initiating LD therapy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm B)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm C)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm D)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm A1)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm E)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Multiple Dose - Arm F)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
|
Eksperimentel: P-MUC1C-ALLO1 CAR-T cells (Single Dose - Arm M)
|
P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C. Rimiducid (safety switch activator) may be administered as indicated. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of P-MUC1C-ALLO1
Tidsramme: Baseline through Day 28
|
Number of subjects with a dose limiting toxicity (DLT) |
Baseline through Day 28
|
|
Evaluate the overall safety and tolerability profile of P-MUC1C-ALLO1
Tidsramme: Baseline through 15 years
|
Frequency and severity of adverse events |
Baseline through 15 years
|
|
Evaluate the preliminary efficacy of P-MUC1C-ALLO1
Tidsramme: Baseline through 15 years
|
According to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, secondarily Immune Response Evaluation Criteria in Solid Tumors (iRECIST): Overall Response Rate (ORR) |
Baseline through 15 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Simon Heidegger, M.D., Lead Medical Director, Oncology, Genentech Research Early Development
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Sygdomme i det endokrine system
- Stomatognatiske sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Nyresygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Tarmsygdomme
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Gastrointestinale neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Gastrointestinale sygdomme
- Mavesygdomme
- Intestinale neoplasmer
- Endetarmssygdomme
- Kønssygdomme, kvindelige
- Lungesygdomme
- Neoplasmer i endokrine kirtler
- Neoplasmer i hoved og hals
- Pancreassygdomme
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Tyktarmssygdomme
- Lungeneoplasmer
- Ovariesygdomme
- Adnexale sygdomme
- Genitale neoplasmer, kvindelige
- Gonadale lidelser
- Hudsygdomme
- Brystsygdomme
- Urologiske neoplasmer
- Karcinom
- Otorhinolaryngologiske sygdomme
- Nyre-neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Pharyngeale neoplasmer
- Otorhinolaryngologiske neoplasmer
- Nasopharyngeale sygdomme
- Pharyngeale sygdomme
- Karcinom, pladecelle
- Hud- og bindevævssygdomme
- Planocellulært karcinom i hoved og hals
- Neoplasmer i maven
- Kolorektale neoplasmer
- Ovariale neoplasmer
- Brystneoplasmer
- Bugspytkirtel neoplasmer
- Karcinom, nyrecelle
- Karcinom, ikke-småcellet lunge
- Nasopharyngeale neoplasmer
Andre undersøgelses-id-numre
- P-MUC1C-ALLO1-001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .